Cite
HARVARD Citation
von Pawel, J. et al. (2019). Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. European journal of cancer. pp. 124-132. [Online].